Skip to Content

Liptruzet FDA Approval History

FDA Approved: Yes (Discontinued) (First approved May 3, 2013)
Brand name: Liptruzet
Generic name: atorvastatin and ezetimibe
Dosage form: Tablets
Company: Merck
Treatment for: High Cholesterol, Familial Heterozygous

Marketing Status: Discontinued

Liptruzet (atorvastatin and ezetimibe) is a statin (HMG-CoA reductase inhibitor) and cholesterol absorption inhibitor combination indicated for the treatment of hyperlipidemia.

Development Timeline for Liptruzet

DateArticle
May  3, 2013ApprovalFDA Approves Merck‚Äôs Liptruzet (ezetimibe and atorvastatin), a New Product That Can Help Lower LDL Cholesterol
Jan  3, 2013Merck Announces FDA Acknowledgement of Resubmission of New Drug Application for Ezetimibe/Atorvastatin Tablets

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.